肉豆蔻酰化
癌症研究
淋巴瘤
癌症
细胞培养
癌细胞
MAPK/ERK通路
细胞
信号转导
激酶
生物
细胞生物学
免疫学
生物化学
磷酸化
遗传学
作者
Erwan Beauchamp,Megan C. Yap,Aishwarya Iyer,Maneka A. Perinpanayagam,Jay M. Gamma,Krista Vincent,Manikandan Lakshmanan,Anandhkumar Raju,Vinay Tergaonkar,Soo Yong Tan,Soon Thye Lim,Wei-Feng Dong,Lynne-Marie Postovit,Kevin D. Read,David W. Gray,Paul G. Wyatt,John R. Mackey,Luc G. Berthiaume
标识
DOI:10.1038/s41467-020-18998-1
摘要
Abstract Myristoylation, the N-terminal modification of proteins with the fatty acid myristate, is critical for membrane targeting and cell signaling. Because cancer cells often have increased N-myristoyltransferase (NMT) expression, NMTs were proposed as anti-cancer targets. To systematically investigate this, we performed robotic cancer cell line screens and discovered a marked sensitivity of hematological cancer cell lines, including B-cell lymphomas, to the potent pan-NMT inhibitor PCLX-001. PCLX-001 treatment impacts the global myristoylation of lymphoma cell proteins and inhibits early B-cell receptor (BCR) signaling events critical for survival. In addition to abrogating myristoylation of Src family kinases, PCLX-001 also promotes their degradation and, unexpectedly, that of numerous non-myristoylated BCR effectors including c-Myc, NFκB and P-ERK, leading to cancer cell death in vitro and in xenograft models. Because some treated lymphoma patients experience relapse and die, targeting B-cell lymphomas with a NMT inhibitor potentially provides an additional much needed treatment option for lymphoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI